Skip to main content
NCBI home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1986 Oct;66(1):77–87.

A sensitive radioimmunoassay for alpha-interferon: circulating alpha-interferon-like substance in the plasma of healthy individuals and rheumatoid arthritis patients.

S Shiozawa, K Chihara, K Shiozawa, T Fujita, H Ikegami, S Koyama, M Kurimoto
PMCID: PMC1542641  PMID: 3802576

Abstract

A radioimmunoassay for circulating alpha-interferon (IFN alpha) has been developed using lymphoblastoid IFN alpha. The assay was specific for IFN alpha, and did not cross-react with IFN beta, IFN gamma, or ACTH, while it was specifically inhibited by recombinant IFN alpha. The radioimmunoassay (y) correlated linearly with the virus inhibition assay (x), with a regression line of y on x of y = 0.659x + 245 (u) (P less than 0.01). alpha-Interferon-like substance (IFN alpha-LS) was extracted and concentrated from plasma either by silicic acid or by antibody immunoadsorption. Serial dilutions of plasma and extracted samples of plasma showed dilution curves identical to those of standard IFN alpha, suggesting the presence of endogenous IFN alpha in human plasma. The circulating IFN alpha-LS of healthy individuals aged 20 to 45 was 0.207 +/- 0.055 ng/ml in males (n = 48) and 0.172 +/- 0.076 ng/ml in females (n = 34). Gel filtration studies on a Sephadex G-75 column suggested that circulating IFN alpha-LS exists in a fragmented form, inactive in virus inhibition assays, in the plasma of healthy individuals. The finding may help explain why biological IFN alpha is often undetectable in the plasma of healthy donors, yet is detectable by radioimmunoassay. Circulating IFN alpha-LS in the plasma of healthy individuals declined gradually with age. IFN alpha-LS was significantly decreased in the plasma of rheumatoid arthritis patients, when compared with the value found in the age and sex-matched healthy controls and in osteoarthritis patients (P less than 0.0001). The decrease was related neither to treatment nor to disease activity. IFN alpha-LS was, however, not decreased in the plasma of vasculitis patients. Decreased IFN alpha-LS in rheumatoid arthritis may be important from pathogenetic and therapeutic standpoints.

Full text

PDF
77

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allen G., Fantes K. H., Burke D. C., Morser J. Analysis and purification of human lymphoblastoid (Namalwa) interferon using a monoclonal antibody. J Gen Virol. 1982 Nov;63(Pt 1):207–212. doi: 10.1099/0022-1317-63-1-207. [DOI] [PubMed] [Google Scholar]
  2. Buffet-Janvresse C., Hovanessian A. G. Enzyme markers for the presence of circulating interferon: 2-5A synthetase in blood lymphocytes and protein kinase in platelet-rich plasma. Proc Soc Exp Biol Med. 1984 Feb;175(2):169–175. doi: 10.3181/00379727-175-41783. [DOI] [PubMed] [Google Scholar]
  3. Combe B., Pope R., Darnell B., Talal N. Modulation of natural killer cell activity in the rheumatoid joint and peripheral blood. Scand J Immunol. 1984 Dec;20(6):551–558. doi: 10.1111/j.1365-3083.1984.tb01038.x. [DOI] [PubMed] [Google Scholar]
  4. DeGré M., Mellbye O. J., Clarke-Jenssen O. Immune interferon in serum and synovial fluid in rheumatoid arthritis and related disorders. Ann Rheum Dis. 1983 Dec;42(6):672–676. doi: 10.1136/ard.42.6.672. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Dobloug J. H., Førre O., Kvien T. K., Egeland T., Degré M. Natural killer (NK) cell activity of peripheral blood, synovial fluid, and synovial tissue lymphocytes from patients with rheumatoid arthritis and juvenile rheumatoid arthritis. Ann Rheum Dis. 1982 Oct;41(5):490–494. doi: 10.1136/ard.41.5.490. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Faure G., Bene M. C., Tamisier J. N., Thomas P. Monoclonal antibody (HNK 1-Leu 7) defined lymphoid cells in the blood of rheumatoid arthritis patients. Arthritis Rheum. 1983 Sep;26(9):1173–1175. doi: 10.1002/art.1780260921. [DOI] [PubMed] [Google Scholar]
  7. Fradelizi D., Gresser I. Interferon inhibits the generation of allospecific suppressor T lymphocytes. J Exp Med. 1982 Jun 1;155(6):1610–1622. doi: 10.1084/jem.155.6.1610. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Goto M., Tanimoto K., Chihara T., Horiuchi Y. Natural cell-mediated cytotoxicity in Sjögren's syndrome and rheumatoid arthritis. Arthritis Rheum. 1981 Nov;24(11):1377–1382. doi: 10.1002/art.1780241107. [DOI] [PubMed] [Google Scholar]
  9. Goto M., Zvaifler N. J. Impaired killer cell generation in the autologous mixed leukocyte reaction by rheumatoid arthritis lymphocytes. Arthritis Rheum. 1985 Jul;28(7):731–741. doi: 10.1002/art.1780280703. [DOI] [PubMed] [Google Scholar]
  10. Gresser I., Belardelli F., Maury C., Maunoury M. T., Tovey M. G. Injection of mice with antibody to interferon enhances the growth of transplantable murine tumors. J Exp Med. 1983 Dec 1;158(6):2095–2107. doi: 10.1084/jem.158.6.2095. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Herberman R. B., Ortaldo J. R., Djeu J. Y., Holden H. T., Jett J., Lang N. P., Rubinstein M., Pestka S. Role of interferon in regulation of cytotoxicity by natural killer cells and macrophages. Ann N Y Acad Sci. 1980;350:63–71. doi: 10.1111/j.1749-6632.1980.tb20608.x. [DOI] [PubMed] [Google Scholar]
  12. Hooks J. J., Jordan G. W., Cupps T., Moutsopoulos H. M., Fauci A. S., Notkins A. L. Multiple interferons in the circulation of patients with systemic lupus erythematosus and vasculitis. Arthritis Rheum. 1982 Apr;25(4):396–400. doi: 10.1002/art.1780250406. [DOI] [PubMed] [Google Scholar]
  13. Hooks J. J., Moutsopoulos H. M., Geis S. A., Stahl N. I., Decker J. L., Notkins A. L. Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med. 1979 Jul 5;301(1):5–8. doi: 10.1056/NEJM197907053010102. [DOI] [PubMed] [Google Scholar]
  14. Huang K. Y., Donahoe R. M., Gordon F. B., Dressler H. R. Enhancement of phagocytosis by interferon-containing preparations. Infect Immun. 1971 Nov;4(5):581–588. doi: 10.1128/iai.4.5.581-588.1971. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Johnson H. M., Baron S. The nature of the suppressive effect of interferon and interferon inducers on the in vitro immune response. Cell Immunol. 1976 Jul;25(1):106–115. doi: 10.1016/0008-8749(76)90100-3. [DOI] [PubMed] [Google Scholar]
  16. Kramer P., ten Kate F. W., Bijnen A. B., Jeekel J., Weimar W. Recombinant leucocyte interferon A induces steroid-resistant acute vascular rejection episodes in renal transplant recipients. Lancet. 1984 May 5;1(8384):989–990. doi: 10.1016/s0140-6736(84)92327-4. [DOI] [PubMed] [Google Scholar]
  17. Leanderson T., Hillörn V., Holmberg D., Larsson E. L., Lundgren E. Selective effects of interferon on distinct sites of the T lymphocyte triggering process. J Immunol. 1982 Aug;129(2):490–494. [PubMed] [Google Scholar]
  18. Mantei N., Schwarzstein M., Streuli M., Panem S., Nagata S., Weissmann C. The nucleotide sequence of a cloned human leukocyte interferon cDNA. Gene. 1980 Jun;10(1):1–10. doi: 10.1016/0378-1119(80)90137-7. [DOI] [PubMed] [Google Scholar]
  19. Matsuo A., Hayashi S., Kishida T. Production and purification of human leukocyte interferon. Jpn J Microbiol. 1974 Jan;18(1):21–27. doi: 10.1111/j.1348-0421.1974.tb00739.x. [DOI] [PubMed] [Google Scholar]
  20. Minato N., Reid L., Cantor H., Lengyel P., Bloom B. R. Mode of regulation of natural killer cell activity by interferon. J Exp Med. 1980 Jul 1;152(1):124–137. doi: 10.1084/jem.152.1.124. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Miyoshi I., Hiraki S., Tsubota T., Kubonishi I., Matsuda Y., Nakayama T., Kishimoto H., Kimura I., Masuji H. Human B cell, T cell and null cell leukaemic cell lines derived from acute lymphoblastic leukaemias. Nature. 1977 Jun 30;267(5614):843–844. doi: 10.1038/267843a0. [DOI] [PubMed] [Google Scholar]
  22. Mogensen K. E., Pyhälä L., Cantell K. Raising antibodies to human leukocyte interferon. Acta Pathol Microbiol Scand B. 1975 Oct;83(5):443–450. doi: 10.1111/j.1699-0463.1975.tb00123.x. [DOI] [PubMed] [Google Scholar]
  23. Neighbour P. A., Grayzel A. I. Interferon production of vitro by leucocytes from patients with systemic lupus erythematosus and rheumatoid arthritis. Clin Exp Immunol. 1981 Sep;45(3):576–582. [PMC free article] [PubMed] [Google Scholar]
  24. Ortaldo J. R., Phillips W., Wasserman K., Herberman R. B. Effects of metabolic inhibitors on spontaneous and interferon-boosted human natural killer cell activity. J Immunol. 1980 Oct;125(4):1839–1844. [PubMed] [Google Scholar]
  25. Panem S., Check I. J., Henriksen D., Vilcek J. Antibodies to alpha-interferon in a patient with systemic lupus erythematosus. J Immunol. 1982 Jul;129(1):1–3. [PubMed] [Google Scholar]
  26. Perussia B., Trinchieri G. Inactivation of natural killer cell cytotoxic activity after interaction with target cells. J Immunol. 1981 Feb;126(2):754–758. [PubMed] [Google Scholar]
  27. Pidot A. L. Dye uptake assay: an efficient and sensitive method for human interferon titration. Appl Microbiol. 1971 Oct;22(4):671–677. doi: 10.1128/am.22.4.671-677.1971. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Pinals R. S., Baum J., Bland J., Fosdick W. M., Kaplan S. B., Masi A. T., Mitchell D. M., Ropes M. W., Short C. L., Sigler J. W. Preliminary criteria for clinical remission in rheumatoid arthritis. Bull Rheum Dis. 1982;32(1):7–10. [PubMed] [Google Scholar]
  29. Preble O. T., Black R. J., Friedman R. M., Klippel J. H., Vilcek J. Systemic lupus erythematosus: presence in human serum of an unusual acid-labile leukocyte interferon. Science. 1982 Apr 23;216(4544):429–431. doi: 10.1126/science.6176024. [DOI] [PubMed] [Google Scholar]
  30. ROPES M. W., BENNETT G. A., COBB S., JACOX R., JESSAR R. A. 1958 Revision of diagnostic criteria for rheumatoid arthritis. Bull Rheum Dis. 1958 Dec;9(4):175–176. [PubMed] [Google Scholar]
  31. Schultz R. M., Chirigos M. A., Heine U. I. Functional and morphologic characteristics of interferon-treated macrophages. Cell Immunol. 1978 Jan;35(1):84–91. doi: 10.1016/0008-8749(78)90128-4. [DOI] [PubMed] [Google Scholar]
  32. Schultz R. M., Papamatheakis J. D., Chirigos M. A. Interferon: an inducer of macrophage activation by polyanions. Science. 1977 Aug 12;197(4304):674–676. doi: 10.1126/science.877584. [DOI] [PubMed] [Google Scholar]
  33. Sidwell R. W., Huffman J. H. Use of disposable micro tissue culture plates for antiviral and interferon induction studies. Appl Microbiol. 1971 Nov;22(5):797–801. doi: 10.1128/am.22.5.797-801.1971. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Skurkovich S. V., Skorikova A. S., Eremkina E. I. Enhancement by interferon of lymphocyte cytotoxicity in normal individuals to cells of human lymphoblastoid lines. J Immunol. 1978 Sep;121(3):1173–1176. [PubMed] [Google Scholar]
  35. Svet-Moldavsky G. J., Chernyakhovskaya I. J. Interferon and the interaction of allogeneic normal and immune lymphocytes with L-cells. Nature. 1967 Sep 16;215(5107):1299–1300. doi: 10.1038/2151299a0. [DOI] [PubMed] [Google Scholar]
  36. Tan E. M., Cohen A. S., Fries J. F., Masi A. T., McShane D. J., Rothfield N. F., Schaller J. G., Talal N., Winchester R. J. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982 Nov;25(11):1271–1277. doi: 10.1002/art.1780251101. [DOI] [PubMed] [Google Scholar]
  37. Targan S., Dorey F. Dual mechanism of interferon augmentation of natural killer cytotoxicity (NKCC). Ann N Y Acad Sci. 1980;350:121–129. doi: 10.1111/j.1749-6632.1980.tb20613.x. [DOI] [PubMed] [Google Scholar]
  38. Trinchieri G., Santoli D. Anti-viral activity induced by culturing lymphocytes with tumor-derived or virus-transformed cells. Enhancement of human natural killer cell activity by interferon and antagonistic inhibition of susceptibility of target cells to lysis. J Exp Med. 1978 May 1;147(5):1314–1333. doi: 10.1084/jem.147.5.1314. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Ytterberg S. R., Schnitzer T. J. Serum interferon levels in patients with systemic lupus erythematosus. Arthritis Rheum. 1982 Apr;25(4):401–406. doi: 10.1002/art.1780250407. [DOI] [PubMed] [Google Scholar]
  40. Zvaifler N. J. The immunopathology of joint inflammation in rheumatoid arthritis. Adv Immunol. 1973;16(0):265–336. doi: 10.1016/s0065-2776(08)60299-0. [DOI] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES